参考文献/References:
[1] Tuttolomondo A,Di Raimondo D,Pecoraro R,et al.Atherosclerosis as an inflammatory disease[J].Curr Pharm Des,2012,18(28):4266-4288.
[2] Cai A,Zheng D,Qiu R,et al.Lipoprotein-associated phospholipase A2(Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment[J].Dis Markers,2013,34(5):323-331.
[3] Holzer M,Wolf P,Inzinger M,et al.Anti-psoriatic therapy recovers high-density lipoprotein composition and function[J].J Invest Dermatol,2014,134(3):635-642.
[4] Stafforini DM,Mcintyre TM,Carter ME,et al.Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor[J].J Biol Chem,1987,262(9):4215-4222.
[5] Brilakis ES,Khera A,Mcguire DK,et al.Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study[J].Atherosclerosis,2008,199(1):110-115.
[6] Casas JP,Ninio E,Panayiotou A,et al.PLA2G7 genotype, Lipoprotein-Associated phospholipase a(2)activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European ancestry[J].Circulation,2010,121(21):2274-2284.
[7] Feng LM,Feng GF,Chen Y.Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum[J].Lipids Health Dis,2014,13(6):6.
[8] Rallidis LS,Tellis CC,Lekakis JA,et al.Lipoprotein-Associated phospholipase a(2)bound on High-Density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients[J].J Am Coll Cardiol,2012,60(20):2053-2060.
[9] Li SB,Yang F,Jing L,et al.Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease[J].Exp Ther Med,2013,5(5):1451-1455.
[10] Sasabe N,Keyamura Y,Obama T,et al.Time course-changes in phosphatidylcholine profile during oxidative modification of low-density lipoprotein[J].Lipids Health Dis,2014,13(13):48.
[11] Maiolino G,Lenzini L,Pedon L,et al.Lipoprotein-associated phospholipase A(2)single-nucleotide polymorphisms and cardiovascular events in patients with coronary artery disease[J].Journal of Cardiovascular Medicine,2015,16(1, SI):29-36.
[12] Yadav R,Liu Y,Kwok S,et al.Effect of Extended-Release niacin on High-Density lipoprotein(HDL)functionality, lipoprotein metabolism, and mediators of vascular inflammation in Statin-Treated patients[J].J Am Heart Assoc,2015,4(9):e001508.
[13] Gu X,Hou JB,Yang S,et al.Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome?[J].Coron Artery Dis,2014,25(1):10-15.
[14] Katan M,Moon YP,Paik MC,et al.Lipoprotein-associated phospholipase A2 is associated with atherosclerotic stroke risk: the Northern Manhattan Study[J].PLoS One,2014,9(1):e83393.
[15] Madjid M,Ali M,Willerson JT.Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature[J].Tex Heart Inst J,2010,37(1):25-39.
[16] Thompson A,Gao P,Jimth G,et al.Lipoprotein-associated phospholipase A2 and mortality: collaborative analysis of 32 prospective studies[J].Lancet,2010,375(9725):1536-1544.
[17] Cucchiara BL,Messe SR,Sansing L,et al.Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA[J].Stroke,2009,40(7):2332-2336.
[18] Gorelick PB.Lipoprotein-Associated phospholipase a2 and risk of stroke[J].Am J Cardiol,2008,101(12A):S34-S40.
[19] 中国老年学会心脑血管病专业委员会.脂蛋白相关磷脂酶A2 临床应用专家建议(2015)[J].中华心血管病杂志,2015,43(10):843-847.
[20] Persson M,Berglund G,Nelson JJ,et al.Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden[J].Atherosclerosis,2008,200(1):191-198.
[21] Nambi V,Hoogeveen RC,Chambless L,et al.Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities(ARIC)study[J].Stroke,2009,40(2):376-381.
[22] 夏文翠,胡中扬,宋治.脂蛋白相关磷脂酶A2与缺血性脑卒中相关性的Meta分析[J].中南大学学报(医学版),2017,42(2):208-214.
[23] Delgado P,Chacón P,Penalba A,et al.Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting[J].Atherosclerosis,2012,220(2):532-536.
[24] Oei HH,Van Der Meer IM,Hofman A,et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study[J].Circulation,2005,111(5):570-575.
[25] Elkind MS,Tai WL,Coates K,et al.Lipoprotein-Associated phospholipase a(2)activity and risk of recurrent stroke[J].Cerebrovascular Diseases,2009,27(1):42-50.
[26] Massot A,Pelegri D,Penalba A,et al.Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease[J].Atherosclerosis,2011,218(1):181-187.
[27] Delgado P,Chacón P,Penalba A,et al.Lipoprotein-associated phospholipase A(2)activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients[J].Cerebrovasc Dis,2012,33(2):150-158.
[28] Elkind MS,Leon V,Moon YP,et al.High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction[J].Stroke,2009,40(10):3233-3237.
[29] Lin JX,Zheng HW,Cucchiara BL,et al.Association of Lp-PLA(2)-A and early recurrence of vascular events after TIA and minor stroke[J].Neurology,2015,85(18):1585-1591.
[30] Kara H,Akinci M,Degirmenci S,et al.High-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke[J].Neuropsychiatr Dis Treat,2014,10:1451-1457.
[31] 郭荷娜,王妮,王倩,等.急性脑梗死患者血浆脂蛋白相关磷脂酶A2与病情轻重关系的研究[J].中国卫生检验杂志,2016,26(18):2666-2667, 2670.
[32] Liu YS,Hu XB,Li HZ,et al.Association of lipoprotein-associated phospholipase A2 with characteristics of vulnerable coronary atherosclerotic plaques[J].Yonsei Med J,2011,52(6):914-922.
[33] Liu J,Wang W,Qi YE,et al.Association between the Lipoprotein-Associated Phospholipase A2 Activity and the Progression of Subclinical Atherosclerosis[J].J Atheroscler Thromb,2014,21(6):532-542.
[34] Colley KJ,Wolfert RL,Cobble ME.Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk[J].EPMA J,2011,2(1):27-38.
[35] 冯文清,石彦彦,吴保鑫,等.人血浆脂蛋白相关磷脂酶A2和脑梗死患者颈动脉斑块稳定性之间的关联[J].卒中与神经疾病,2018,25(1):25-27.
[36] Wang Y,Zhang J,Qian Y,et al.Association of Lp-PLA2 mass and aysmptomatic intracranial and extracranial arterial stenosis in hypertension patients[J].PLoS One,2015,10(6):e0130473.
[37] 王惠,董万利,马先军,等.影响进展性卒中的相关因素分析[J].中华脑血管病杂志(电子版),2014,8(1):51-54.
[38] 潘杨,张丽.脂蛋白相关磷脂酶A2与轻型缺血性卒中早期神经功能恶化风险分层的相关性研究[J].南京医科大学学报(自然科学版),2016,36(8):991-994.
[39] 王惠,马先军,董万利,等.脂蛋白相关磷脂酶A_2对大动脉粥样硬化型脑梗死病情进展的预测价值[J].脑与神经疾病杂志,2017,25(7):407-410.
[40] Goldstein LB,Bushnell CD,Adams RJ,et al.Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J].Stroke,2011,42(2):517-584.
[41] Perk J,De Backer G,Gohlke H,et al.European guidelines on cardiovas-cular disease prevention in clinical practice(version 2012):the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice(constituted by representatives of nine societies and by invited experts)[J].Int J Behav Med,2012,19(4):403-488.